<DOC>
	<DOC>NCT01765231</DOC>
	<brief_summary>The purpose of this study is to identify the effect of prophylactic entecavir in HBsAg Negative/HBcAb Positive/hepatitis B virus DNA Negative patients with lymphoma.</brief_summary>
	<brief_title>Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma</brief_title>
	<detailed_description>The purpose of this study is to identify the effect of prophylactic entecavir in HBsAg Negative/HBcAb Positive/hepatitis B virus DNA Negative patients with lymphoma are randomized into entecavir prophylaxis group or observation group. In entecavir prophylaxis group, entecavir 0.5 mg/day orally is initiate on day 1 of the first course of antitumor therapy, and will be continued until at least 6 months after completion of antitumor therapy. In observation group, entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>treatmentnaive patients with lymphoma HBsAg negative/HBcAb positive/hepatitis B virus DNA negative at baseline treated with chemotherapy and/or immunosuppressive therapy life expectancy of more than 3 months younger than 18 years old HBsAg positive or HBcAb negative or hepatitis B virus DNA positive at baseline pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Hepatitis B virus</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>